Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surgery Plus Chemotherapy vs Chemotherapy Alone in Oligometastatic Stage IV Gastric Cancer
NCT03042169Phase 3Terminated
- Sponsor
- CHU de Lille
- Start
- Aug 2021
- Primary completion
- Aug 2024
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in gastric adenocarcinoma (2 arms), sponsored by CHU de Lille. Primary endpoint: Overall Survival up to 2 years. Started Aug 2021; status: terminated.
02
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT03042169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03042169.